El Saf

This trial investigates two medications to see which works better for women with overactive bladder OAB, a condition causing sudden urges to urinate, frequent bathroom visits, and sometimes leakage. Researchers aim to compare low dose tadalafil and solifenacin for managing OAB symptoms such as urgency and frequent urination. The study is a randomized, phase 4 clinical trial focused on women aged 18 to 75 with OAB symptoms lasting at least three months. Participants will be randomly assigned to one of two groups. One group will take tadalafil 5 mg once daily, and the other group will take solifenacin 5 mg once daily. Both treatments will continue for 12 weeks. During this time, participants will keep a bladder diary and complete questionnaires about their symptoms and quality of life. Throughout the 12-week study, participants will attend several visits for simple urine flow and bladder function tests. Researchers will track changes in OAB symptoms using the Overactive Bladder Symptom Score and other questionnaires. They will also monitor side effects and overall quality of life. The main goal is to find out which medicine reduces OAB symptoms more effectively.